WEKO3
インデックスリンク
アイテム
Neutralizing epitopes of RSV and palivizumab resistance in Japan
https://fmu.repo.nii.ac.jp/records/2001942
https://fmu.repo.nii.ac.jp/records/2001942c920d2b3-dbdf-4afa-9d6d-1596481052f5
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
FksmJMedSci_63_p127.pdf (216.4 KB)
|
|
| Item type | デフォルトアイテムタイプ（フル）fmu(1) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2017-12-27 | |||||||||
| タイトル | ||||||||||
| タイトル | Neutralizing epitopes of RSV and palivizumab resistance in Japan | |||||||||
| 言語 | en | |||||||||
| 作成者 |
Hashimoto, Koichi
× Hashimoto, Koichi
× Hosoya, Mitsuaki
|
|||||||||
| 権利情報 | ||||||||||
| 言語 | en | |||||||||
| 権利情報 | © 2017 The Fukushima Society of Medical Science | |||||||||
| 主題 | ||||||||||
| 言語 | en | |||||||||
| 主題Scheme | Other | |||||||||
| 主題 | RSV | |||||||||
| 主題 | ||||||||||
| 言語 | en | |||||||||
| 主題Scheme | Other | |||||||||
| 主題 | neutralizing epitope | |||||||||
| 主題 | ||||||||||
| 言語 | en | |||||||||
| 主題Scheme | Other | |||||||||
| 主題 | palivizumab | |||||||||
| 主題 | ||||||||||
| 言語 | en | |||||||||
| 主題Scheme | Other | |||||||||
| 主題 | resistance | |||||||||
| 主題 | ||||||||||
| 言語 | en | |||||||||
| 主題Scheme | Other | |||||||||
| 主題 | Japan | |||||||||
| 内容記述 | ||||||||||
| 内容記述タイプ | Abstract | |||||||||
| 内容記述 | Respiratory Syncytial Virus (RSV) is one of the most important viral pathogen related to acute lower respiratory infection in young children. The virus surface envelope contains the G, F, and SH proteins as spike proteins. The F protein is considered to be a major antigenic target for the neutralizing (NT) epitope as only the F protein is essential for cell infection among the three viral envelope proteins, and it is more highly conserved than the G protein. Recently, four antigenic targets related to NT activity have been reported;site I, site II, site IV, and site zero (0). Site II is the target for palivizumab used throughout the world to suppress severe RSV infection as passive immunity in high-risk children since 1998. Under the recent conditions in which indications for palivizumab administered subjects are being expanded, palivizumab-resistant mutations have been confirmed overseas in children with RSV infection, although they remain infrequent. Therefore, continuous genetic analysis of the palivizumab-binding region of the F protein is necessary. In addition, as vaccine development progresses, RSV infection control is expected to improve greatly over the next decade. | |||||||||
| 言語 | en | |||||||||
| 出版者 | ||||||||||
| 出版者 | The Fukushima Society of Medical Science | |||||||||
| 言語 | en | |||||||||
| 言語 | ||||||||||
| 言語 | eng | |||||||||
| 資源タイプ | ||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||
| 資源タイプ | journal article | |||||||||
| 出版タイプ | ||||||||||
| 出版タイプ | VoR | |||||||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||||
| 関連情報 | ||||||||||
| 関連タイプ | isIdenticalTo | |||||||||
| 識別子タイプ | DOI | |||||||||
| 関連識別子 | https://doi.org/10.5387/fms.2017-09 | |||||||||
| 関連情報 | ||||||||||
| 識別子タイプ | PMID | |||||||||
| 関連識別子 | 28867684 | |||||||||
| 関連情報 | ||||||||||
| 識別子タイプ | ICHUSHI | |||||||||
| 関連識別子 | 2019100222 | |||||||||
| 収録物識別子 | ||||||||||
| 収録物識別子タイプ | PISSN | |||||||||
| 収録物識別子 | 0016-2590 | |||||||||
| 収録物識別子 | ||||||||||
| 収録物識別子タイプ | EISSN | |||||||||
| 収録物識別子 | 2185-4610 | |||||||||
| 収録物識別子 | ||||||||||
| 収録物識別子タイプ | NCID | |||||||||
| 収録物識別子 | AA0065246X | |||||||||
| 書誌情報 |
en : Fukushima Journal of Medical Science 巻 63, 号 3, p. 127-134, 発行日 2017 |
|||||||||
